OncLive TV

James "Tate" T. Thigpen, MD, Professor of Medicine, Director, Division of Medical Oncology, University of Mississippi School of Medicine, discusses the comparison of treatment options in ovarian cancer.

Paul Ruff, MD, director of medical oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses the analysis of prior bevacizumab in the VELOUR trial in patients with metastatic colorectal cancer.

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses the benefits of combining BRAF and MEK inhibitors when treating melanoma.

David P. Carbone, MD, PhD, a professor in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, discusses potential biomarkers in lung cancer.

Jo Anne Zujewski, MD, head, breast cancer therapeutics, cancer therapy evaluation program, National Cancer Institute (NCI), discusses the development of drugs to treat patients with breast cancer.

Maurie Markman, MD, from the Cancer Treatment Centers of America, discusses the discovery of mutations and targets in ovarian cancer and the current progress being made in the development of a "breakthrough" agent for ovarian cancer.

Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, Attending Physician, Memorial Sloan-Kettering Cancer Center, discusses his optimism surrounding immunotherapy for cancer care.

Silvia Novello, MD, PhD, assistant professor, Thoracic Oncology Unit, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses some of the "gray areas" that require more research for the treatment of patients with lung cancer.

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the management of adverse events (AEs) from treatment with immunotherapies.

Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the pros and cons of using the Ki67 as a prognostic marker in breast cancer.

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the design of a phase II study of selumetinib versus temozolomide in uveal melanoma with GNAQ/GNA11 mutations.

Harvey I. Pass, MD, Stephen E. Banner Professor of Thoracic Oncology, Vice-Chair Research, Department of Cardiothoracic Surgery, Division Chief, General Thoracic Surgery, NYU Langone Medical Center, discusses blood-based markers in lung cancer.

Kathy S. Albain, MD, medical oncologist, Loyola University Chicago, professor, Stritch School of Medicine, director, Breast Clinical Research Program, Thoracic Oncology Research Program, Cardinal Bernardin Cancer Center, discusses staging versus biology in breast cancer.

Jeffrey A. Sosman, MD, professor of medicine, Director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, describes the mechanism of action of ipilimumab in patients with melanoma.

Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, discusses an analysis of the VELOUR trial.

Giorgio V. Scagliotti, MD, PhD, head, Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses treating epidermal growth factor receptor- (EGFR) mutated tumors with afatinib.

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the role of Bruton's tyrosine kinase (BTK) in chronic lymphocytic leukemia (CLL).

Minetta Liu, MD, breast cancer specialist, Mayo Clinic, Rochester, Minnesota, discusses the limitations of radiology in metastatic breast cancer treatment.

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the approval of radium-223 for patients with bone metastases from prostate cancer.

Roy S. Herbst, MD, PhD, professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the differences of targeting PD-1 and PD-L1 when treating patients with lung cancer.

Rebecca L. Aft, MD, PhD, professor of surgery at the Washington University School of Medicine in St. Louis and a physician at Siteman Cancer Center, discusses the use of bisphosphonates for patients with breast cancer.

S. Gail Eckhardt, MD, professor and head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the wnt pathway and its role in colorectal cancer.

G. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, Professor, Hematology & Medical Oncology, Case Western Reserve University, discusses prior treatment with trastuzumab and the effect on two regimens of paclitaxel.

Paul A. Bunn, Jr, MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor (EGFR) mutation.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

Silvia Novello, MD, PhD, assistant professor, Thoracic Oncology Unit, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses immunotherapy and targeting the MAGE-A3 protein in lung cancer.

Constance D. Lehman, MD, PhD, from the Seattle Cancer Care Alliance, discusses how imaging can guide a women with breast cancer to make treatment decisions.

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, explains the role of PD-1 and PD-L1.

David P. Steensma, MD, from the Dana-Farber Cancer Institute, provides insight into the ODAC decision to recommend approval for a neoadjuvant pertuzumab-containing regimen for patients with HER2-positive breast cancer.

Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses how to improve the strategy of developing treatments for lung cancer.